Galapagos chops into their pipeline, dropping core fields and reorganizing R&D as the BD team hunts for something ‘transformative’

Just 5 months after Gilead gutted its rich partnership with Galapagos following a bitter setback at the FDA, the Belgian biotech is hunkering down and chopping the pipeline in an effort to conserve cash while their BD team pursues a mission to find a “transformative” deal for the company. The…

...

Click to view original post